Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell
Continue reading »Home ยป
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of Pixuvri (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
SEATTLE, July 9, 2018 /PRNewswire/ — CTI BioPharma Corp. (NASDAQ:CTIC) and Servier today announced that the pivotal Phase III trial
Continue reading »